Key result
In-vitro incubation with MMF caused a minor but significant decrease in collagen-induced platelet aggregation compared with vehicle (6% vs 22%, P=0.02).
Why the study?
Studies indicate MMF inhibits collagen-induced platelet aggregation, potentially increasing bleeding risk following MMF therapy.
Does mycophenolate mofetil or mycophenolic acid affect platelet aggregation and activation in blood samples from healthy donors?
Population
Blood samples (n = 6) from healthy donors
Comparison
Vehicle vs MMF vs MPA at clinically relevant concentrations
Design
In-vitro study
Authors
Loading...
MMF's minor in-vitro effect suggests no immediate clinical platelet caution; leaves open in-vivo relevance in patients.
Does mycophenolate mofetil or mycophenolic acid affect platelet aggregation and activation in blood samples from healthy donors?
Absolute Event Rate: 6% vs 22%
p-value: p=0.02
In vitro, mycophenolate mofetil and mycophenolic acid have only a minor inhibitory effect on collagen-induced platelet aggregation, suggesting limited direct impact on platelet function.
Knudsen et al. (2020) studied Healthy donors (n=6). Mycophenolate mofetil (MMF) or mycophenolic acid (MPA) vs. Vehicle was evaluated on Collagen-induced platelet aggregation (p=0.02). In-vitro incubation with MMF caused a minor but significant decrease in collagen-induced platelet aggregation compared with vehicle (6% vs 22%, P=0.02).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: